GlucoTrack, Inc. (GCTK)
NASDAQ: GCTK · Real-Time Price · USD
1.610
-0.003 (-0.19%)
At close: Oct 26, 2026, 4:00 PM EDT
1.470
-0.140 (-8.70%)
After-hours: Oct 26, 2026, 7:59 PM EDT
Company Description
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States.
The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021.
GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
GlucoTrack, Inc.
| Country | United States |
| Founded | 2001 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Erik Emerson |
Contact Details
Address: 301 Route 17 North, Suite 800 Rutherford, New Jersey 07070 United States | |
| Phone | 201 842 7715 |
| Website | glucotrack.com |
Stock Details
| Ticker Symbol | GCTK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1506983 |
| CUSIP Number | 45824Q887 |
| ISIN Number | US45824Q8877 |
| Employer ID | 98-0668934 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Erik C. Emerson | Chief Executive Officer and Director |
| Dr. Paul V. Goode Ph.D. | Chief Technical Officer and President |
| Avner Gal MBA, MSc.EE | Co-Founder, Chairman Emeritus and Consultant |
| David Malka BA | Co-Founder |
| Vincent Wong | Chief Operations Officer |
| Dr. Mark Tapsak Ph.D. | Chief Scientific Officer |
| Drinda Benjamin | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2026 | 8-K | Current Report |
| Oct 19, 2026 | 8-K | Current Report |
| Oct 14, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 13, 2026 | PRE 14A | Other preliminary proxy statements |
| Oct 13, 2026 | 425 | Filing |
| Oct 13, 2026 | 8-K/A | [Amend] Current report |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 24, 2026 | 424B5 | Filing |
| Sep 24, 2026 | 8-K | Current Report |
| Sep 23, 2026 | 425 | Filing |